archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Performance Summary
    hours worked 2 14 1 96 1 80 Medical treatment injury frequency rate MTIFR Per million hours worked 6 42 4 67 6 60 Days lost frequency rate DLFR 1 Per million hours worked 85 2 155 8 40 9 1 DLFR is a metric not previously reported read more Community 2010 11 2011 12 2012 13 Total contribution US million 26 9 34 1 36 3 read more Environment 2004 05 baseline 2005 06 2006 07 2007 08 2008 09 2009 10 2010 11 2011 12 2012 13 CSL sites for the applicable energy GHG and water data Manufacturing sites in Bern Marburg Kankakee Parkville and Broadmeadows Energy consumption Peta joules 2 1 70 1 69 1 75 1 74 1 77 1 76 1 79 1 86 Greenhouse gas emissions Kilo tonnes 141 142 142 160 160 164 165 168 176 Water consumption Giga litres 1 70 1 74 1 70 2 00 1 87 1 89 1 95 2 02 2 22 CSL sites for the applicable waste data Manufacturing sites in Bern Marburg and Kankakee Manufacturing sites in Bern Marburg Kankakee Broadmeadows and Parkville Waste Kilo tonnes 8 6 8 8 9 9 11 7 15 10 15 4 15 20 16 54 16 96 Waste recycling rate 76 81 78 78 71 69 70 73 74 2008 09 2009 10 data restated to include data for CSL Broadmeadows Australia and Parkville Australia read more Environmental intensity indicators ratios that express our environmental impact per unit of production measure our environmental performance as production levels change For our plasma manufacturing facilities this is expressed in terms of the volume of plasma processed For our vaccine manufacturing facility it is expressed in terms of the number of eggs used in vaccine production A fall in intensity indicates

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255925679556/content/1255925678149/content.htm (2014-01-05)
    Open archived version from archive


  • Job Vacancies
    Benefits How To Apply Newsroom Contact CSL Home Careers Job Vacancies Job Vacancies Find a Career at CSL Location Argentina Australia Austria Belgium Brazil Canada Denmark France Germany Mexico Switzerland United States Any State Buenos Aires Updating please wait Job Category Accounting Finance Administrative Clerical Business Development Clinical R D Trials Customer Service Distribution Warehousing Education Engineering Facilities Services Healthcare Human Resources Information Technology Laboratory Services Legal Management Manufacturing Marketing

    Original URL path: http://www.csl.com.au/careers/job-vacancies.htm (2014-01-05)
    Open archived version from archive

  • Employee Benefits at CSL Limited
    achieving business objectives CSL recognises and rewards individual and team performance through various financial and non financial rewards Our approach includes giving rewards and offering recognition more immediately than through an annual performance cycle This includes both formal and informal rewards and recognition ranging from nominating individuals for awards to simply saying thank you for a job well done Our employee benefits recognise the work life balance reward superior performance and provide career development opportunities both locally and globally Flexible Work Arrangements In line with our commitment to work life balance and in appropriate circumstances CSL currently offers flexible work arrangements to help you balance your personal and work responsibilities Options include working from home flexible hours part time work and job sharing Global Employee Share Plan The Global Employee Share Plan is a great way for CSL employees to share in the ownership of the business Employees who have been with CSL on an on going basis for at least six months can participate in the program Development Career CSL provides many learning opportunities for employees to access and support continuous learning professional development and personal growth for improved job performance and career enhancement CSL has partnerships with external

    Original URL path: http://www.csl.com.au/careers/employee-benefits.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited - How to apply
    ensuring that fair and effective processes are implemented and adhered to for the recruitment and selection of candidates to meet the organisations needs All selection decisions will be based on merit demonstrating CSL s commitment to providing equal opportunity by assessing candidates according to the skills qualifications and experience inherent in the vacant role During the recruitment process you may be requested to participate in one or more of the

    Original URL path: http://www.csl.com.au/careers/apply.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    February 2012 the company announced its decision to move to US dollar reporting commencing with the 2012 13 financial year US dollars are the pharmaceutical industry standard currency for reporting purposes The move also reflects the increasing predominance of the Company s worldwide sales and operations in US dollars More 27 09 2012 CSL drug candidate in diabetes research breakthrough CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease More 11 09 2012 CSL Biotherapies awarded Pandemic Preparedness Contract by US Government CSL Biotherapies announced that it has been awarded a contract by the United States US Department of Health and Human Services to supply pre pandemic and pandemic vaccine antigens and related services to the US national stockpile More 22 08 2012 Full Year Results Announcement for 2011 12 CSL Limited ASX CSL today announced a net profit after tax of A 983 million for the twelve months ended 30 June 2012 up A 42 million or 4 5 on a reported basis when compared to the prior comparable period This result included an unfavourable foreign exchange impact of

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1255930772663/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • Search News by Date
    Luxembourg Brazil Canada China Denmark France Germany Italy Japan Mexico Netherlands Nordic Spain Switzerland UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom Search News by Date Search Press Releases Please enter a word or phrase to search From date dd

    Original URL path: http://www.csl.com.au/newsroom/search-by-date.htm (2014-01-05)
    Open archived version from archive

  • CSL announces A$950m share buyback
    CSL Home Newsroom CSL announces A 950m share buyback CSL announces A 950m share buyback Melbourne Australia 16 10 2013 CSL Limited ASX CSL today announced a further on market share buyback of up to A 950 million Speaking at CSL s Annual General Meeting in Melbourne today CSL Chairman Professor John Shine said the Board was pleased to continue a buyback program that had clearly delivered benefits for shareholders Buybacks remain an effective way to manage our capital that delivers improved investment returns for shareholders Professor Shine said The announced buyback will be CSL s seventh in eight years The Company has returned approximately 22 per cent of its shares to shareholders since 2005 Professor Shine said that previous six buybacks totalling some A 3 3 billion have contributed a boost to earnings per share in excess of 15 He said earnings per share growth this financial year will again exceed profit growth expectations as shareholders benefit from the ongoing effect of past and current share buybacks At yesterday s closing price of A 65 38 a A 950 million buyback represents approximately 14 5 million CSL shares or around 3 of CSL s issued share capital Download this

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252897139391/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Agreement to settle U.S. antitrust class action litigation Profit outlook re-affirmed, subject to settlement
    the Plasma Protein Therapeutics Association an industry trade association The settlement including payment of US 64m is subject to an approval process by the U S federal court This process is expected to take several months during which time CSL s involvement in the litigation will be on hold Commenting on the settlement CSL s Chief Executive Officer and Managing Director Paul Perreault said While we continue to strongly reject any allegation of wrong doing we have negotiated a settlement of the litigation which we believe is in the best interests of the Company and our shareholders To pursue the case further would have required several more years of management time and focus as well as substantial additional legal costs with no absolute certainty of the outcome Profit outlook 1 at 2012 2013 exchange rates 2 The Company continues to anticipate net profit after tax NPAT growth in line with the guidance provided at the Company s full year result announced on 14 August 2013 subject to today s announcement regarding the settlement of the U S antitrust litigation If approved the settlement represents a one off charge reducing NPAT expectations for fiscal 2014 by US 39m This charge takes anticipated NPAT growth for the current financial year to approximately 7 at 2012 2013 exchange rates 2 Teleconference CSL will today at 2pm Australian Eastern Standard Time hold a conference call to provide additional background to today s announcement and answer any questions that may arise Dial in details Australia 1800 059 809 International 61 7 3145 4003 Download this release Agreement to settle U S antitrust class action litigation Profit outlook re affirmed subject to settlement 0 07Mb For further information please contact Investors Mark Dehring Head of Investor Relations CSL Limited Phone 613 9389 2818 Email mark dehring

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252897039727/prdetail.htm (2014-01-05)
    Open archived version from archive